Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (231-240 of 322) with videos related to

Pageof 33
Sort By:
The Lancet. Haematology|May 8, 2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trialGuillermo Garcia-Manero, Gail Roboz, Katherine Walsh, et al.
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
Innovation (Cambridge (Mass.))|November 12, 2024
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemiaKellie J Archer, Han Fu, Krzysztof Mrózek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2025
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 ResultsMatthew J Wieduwilt, Jun Yin, Oudom Kour, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Blood Advances|January 17, 2024
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trialGail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, et al.
Blood Advances|May 8, 2026
Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance)Wellington F Silva, Jun Yin, Michaela Liedtke, et al.
Journal of Geriatric Oncology|November 1, 2019
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)Heidi D Klepin, Ellen Ritchie, Brittny Major-Elechi, et al.
Blood Cancer Journal|October 6, 2025
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosisAndrew Palmer, Garth Rauscher, Alexa Schoen, et al.
Leukemia|January 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studiesNadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, et al.
Pageof 33

Showing results (231-240 of 322) with videos related to

Sort By:
Pageof 33
The Lancet. Haematology|May 8, 2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trialGuillermo Garcia-Manero, Gail Roboz, Katherine Walsh, et al.
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
Innovation (Cambridge (Mass.))|November 12, 2024
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemiaKellie J Archer, Han Fu, Krzysztof Mrózek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2025
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 ResultsMatthew J Wieduwilt, Jun Yin, Oudom Kour, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Blood Advances|January 17, 2024
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trialGail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, et al.
Blood Advances|May 8, 2026
Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance)Wellington F Silva, Jun Yin, Michaela Liedtke, et al.
Journal of Geriatric Oncology|November 1, 2019
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)Heidi D Klepin, Ellen Ritchie, Brittny Major-Elechi, et al.
Blood Cancer Journal|October 6, 2025
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosisAndrew Palmer, Garth Rauscher, Alexa Schoen, et al.
Leukemia|January 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studiesNadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, et al.
Pageof 33